- Home
- CACC vs BPMC Comparison
CACC vs BPMC Comparison
Compare CACC & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CACC
- BPMC
- Stock Information
- Founded
- CACC 1972
- BPMC 2008
- Country
- CACC United States
- BPMC United States
- Employees
- CACC N/A
- BPMC N/A
- Industry
- CACC Finance: Consumer Services
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- CACC Finance
- BPMC Health Care
- Exchange
- CACC Nasdaq
- BPMC Nasdaq
- Market Cap
- CACC 6.0B
- BPMC 5.8B
- IPO Year
- CACC 1992
- BPMC 2015
- Fundamental
- Price
- CACC $523.52
- BPMC $85.94
- Analyst Decision
- CACC Sell
- BPMC Buy
- Analyst Count
- CACC 2
- BPMC 22
- Target Price
- CACC $475.00
- BPMC $124.29
- AVG Volume (30 Days)
- CACC 72.7K
- BPMC 982.6K
- Earning Date
- CACC 04-29-2025
- BPMC 05-01-2025
- Dividend Yield
- CACC N/A
- BPMC N/A
- EPS Growth
- CACC N/A
- BPMC N/A
- EPS
- CACC 19.88
- BPMC N/A
- Revenue
- CACC $928,200,000.00
- BPMC $508,824,000.00
- Revenue This Year
- CACC $136.69
- BPMC $45.43
- Revenue Next Year
- CACC $5.28
- BPMC $32.80
- P/E Ratio
- CACC $25.97
- BPMC N/A
- Revenue Growth
- CACC 3.23
- BPMC 104.04
- 52 Week Low
- CACC $409.22
- BPMC $80.68
- 52 Week High
- CACC $614.96
- BPMC $121.90
- Technical
- Relative Strength Index (RSI)
- CACC 62.98
- BPMC 38.77
- Support Level
- CACC $496.43
- BPMC $86.99
- Resistance Level
- CACC $521.44
- BPMC $93.04
- Average True Range (ATR)
- CACC 14.18
- BPMC 3.37
- MACD
- CACC 3.92
- BPMC 0.07
- Stochastic Oscillator
- CACC 98.58
- BPMC 12.12
About CACC Credit Acceptance Corporation
Credit Acceptance Corp is a consumer finance company that specializes in automobile loans. These loans are offered through a U.S. nationwide network of automobile dealers that benefit from sales of vehicles to consumers who could otherwise not obtain financing. The company also benefits from repeat and referral sales, and from sales to customers responding to advertisements for financing, but qualify for traditional financing. The company derives its revenue from finance charges, premiums earned on the reinsurance of vehicle service contracts, and other fees. Of these, financing charges, including servicing fees, are by far a source of revenue.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.